Versant Capital Management’s AnaptysBio ANAB Stock Holding History

Versant Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.6K	Hold	454	–	–	﹤0.01%	1705
2026 Q1	$25.2K	Hold	454	–	–	﹤0.01%	1691
2025 Q4	$22K	Hold	454	–	–	﹤0.01%	1577
2025 Q3	$13.9K	Buy	454 +364	+404%	+$8.35K	﹤0.01%	1777
2025 Q2	$2K	Hold	90	–	–	﹤0.01%	2379
2025 Q1	$1.67K	Hold	90	–	–	﹤0.01%	2290
2024 Q4	$1.19K	Buy	+90	New	+$2.18K	﹤0.01%	2156
2019 Q4	–	Sell	-21	Closed	–	–	1345
2019 Q3	$0	Buy	21 +18	+600%	+$856	﹤0.01%	1358
2019 Q2	$0	Sell	3 -4	-57%	-$288	﹤0.01%	1387
2019 Q1	$0	Buy	+7	New	+$483	﹤0.01%	1545

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Versant Capital Management's ANAB Position: Q2 2026 in Review

Versant Capital Management held its AnaptysBio (ANAB) position steady in Q2 2026 at 454 shares worth $30.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1705.

Versant Capital Management first reported a position in ANAB in Q1 2019 and has held it in 10 quarters since. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Versant Capital Management held 454 shares of AnaptysBio worth $30.6K as of Q2 2026.
Versant Capital Management left its AnaptysBio share count unchanged in Q2 2026.
AnaptysBio made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1705 holding.
Versant Capital Management first reported a position in AnaptysBio in Q1 2019 and has held it in 10 quarters since.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.